← Evidence library

BIB_164

Khattak A et al. Distant metastasis-free survival with adjuvant mRNA-4157 (V940) + pembrolizumab vs pembrolizumab alone in resected high-risk melanoma (KEYNOTE-942 / mRNA-4157-P201): phase 2b RCT. Nature 2024. n=157 Stage IIIB-IV resected; RFS HR 0.561; DMFS HR 0.347. First positive personalised neoantigen vaccine + ICI RCT. [Tasks: 17, 18] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

17, 18

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_164/findings.md (research corpus). This page is a short context summary — not individualised medical advice.